Recent studies have focused attention on the potential role of mast cells in the pathogenesis of systemic sclerosis (scleroderma) and other similar fibrosing syndromes.1 An increased density of dermal mast cells has been described in patients with scleroderma,2 the toxic oil syndrome,3 graft versus host disease,4 and in the tight skin mouse model of scleroderma.5 Furthermore, the dermal mast cells of tight skin mice show massive degranulation,6 and treatment with disodium cromoglycate (an inhibitor of mast cell degranulation) has been observed to produce a marked decrease in skin fibrosis.
Mast cells and circulating basophils may release their inflammatory mediators when activated by lymphocyte products or histamine releasing factors secreted from neighbouring mononuclear cells8 also present in the dermis of patients with scleroderma. 9 .After degranulation mast cell granules can be intemalised by fibroblasts, and this interaction may then promote local fibrosis.10 Anti-IgE autoantibodies, previously reported in systemic lupus erythematosus11 and other autoimmune and atopic Accepted for publication 23 July 1988. Correspondence to Dr Lee D Kaufman, HSC-T- 16- disorders,12-15 may represent an additional mechanism for activation of mast cells and their subsequent interaction with fibroblasts in scleroderma. The current study sought to determine the prevalence of anti-IgE autoantibodies in a group of patients with scleroderma stratified according to the extent and duration of disease as well as their potential functional activity as determined by an in vitro basophil release assay.
Patients and methods

PATIENTS
Sixty six patients fulfilled preliminary American Rheumatism Association criteria for classification as definite systemic sclerosis16 and were selected to reflect a balanced stratification of disease extent and duration. Classification as generalised scleroderma required the presence of truncal skin thickening, whereas limited scleroderma described those patients with skin involvement limited to the hands, forearms, face, and feet. Onset of systemic sclerosis was dated from the first non-Raynaud's clinical manifestation, with three years' duration chosen as the divider between those patients with early and those with late systemic sclerosis. ' There was a significant correlation between IgM anti-IgE and total serum IgE concentrations (R=04106; p<0.01), but no relation between IgG anti-IgE and total serum IgE concentrations (p=NS). In addition, the total mean serum IgE concentration in patients was not abnormal. We were unable to demonstrate the ability of these autoantibodies to degranulate circulating basophils. Normal donor basophils were incubated with varying concentrations of sera containing high titre anti-IgE of both IgG and IgM isotypes in vitro, but multiple attempts to induce the release of measurable histamine failed. Furthermore, heating of reactive sera, which may increase the amount of free antibody available,'2 also had no significant effect on in vitro histamine release from basophils.
We selected 24 independent variables for multivariate analysis based on suggested associations with anti-IgE antibodies, including patient age, sex, total skin score, clinical estimates of skin oedema, skin biopsy specimen weights, history of pruritus, presence of digital ischaemic ulcerations, tendon friction rubs, serum anticentromere antibody, serum creatinine, thyroid function profiles, presence of ventricular arrhythmia on 24 hour ambulatory electrocardiography, pulmonary involvement including reduced vital capacity or diffusing capacity, or both, chest radiographic evidence of interstitial fibrosis, release is the aggregation of IgE receptors through the interaction of autoantibodies directed against membrane bound IgE. The inability to demonstrate histamine release after exposure of basophils in vitro to sera containing these autoantibodies raises questions about the significance of their presence. Several factors may play a part in the functional activity of anti-IgE antibodies. Differences in the responsiveness of mast cells and basophils to various secretagogues have been noted23 and may explain why basophils could not be activated in our study. Recent evidence in some patients with systemic lupus erythematosus" showed that the IgG fraction from sera containing high titre anti-IgE antibody can degranulate cutaneous mast cells in situ even though most systemic lupus erythematosus sera cannot degranulate circulating basophils in vitro. Furthermore, the avidity or concentration of these autoantibodies in the circulation may be too low to promote membrane aggregation of IgE. Finally, it may be that the epitope on the IgE molecule reactive with anti-IgE antibodies is not accessible after binding to cell membranes.
In view of the possible role of the mast cell in fibrosis and scleroderma and evidence that anti-IgE autoantibodies occur in other connective tissue and atopic diseases11-5 the current study sought to evaluate the prevalence and possible clinical correlates of these antibodies in various subsets of systemic sclerosis. We found that approximately one third of patients have anti-IgE autoantibodies irrespective of the extent or duration of clinical disease. It is of interest that patients with limited disease appear to have higher mean anti-IgE titres than patients with generalised disease (p<005), but the clinical significance of this finding is at present undefined.
In our patients the number of individuals with IgM anti-IgE autoantibodies was not significantly different from the number in the control population (Fig. 1) 
